CASE BASED DISCUSSIONS

A 26-year-old woman with respiratory decompensation in the immediate postpartum period at Mount Sinai Medical Center in New York City

Daniel R Bunker,¹ Klaus T Meinhof,² Robert J Hiensch,² Olivia Ghaw,¹ Christian D Becker²

¹Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

²Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA

Correspondence to

Dr Daniel Bunker, Division of Rheumatology, Icahn School of Medicine at Mount Sinai, Annenberg 2-80, 1468 Madison Ave, New York, NY 10029, USA; daniel.bunker@mountsinai.org

DRB and KTM contributed equally.

Received 15 May 2015

Revised 22 June 2015

Accepted 15 July 2015

Published Online First

5 August 2015

Klaus Meinhof and Robert Hiensch

A 26-year-old previously healthy woman developed sudden-onset hypoxaemic respiratory failure 3 days post partum. During pregnancy, the patient had displayed haematuria (26–50 red blood cells/high-power field on urine dipstick) and proteinuria (30 mg/dL on urine dipstick), which at the time was not further investigated. The pregnancy and vaginal delivery were otherwise uncomplicated. On the morning of planned discharge from the maternity ward, the patient developed sudden dyspnoea, tachypnoea, tachycardia and severe hypoxaemia (PaO₂ of 48 mm Hg on room air) accompanied by 5 mL of bright red haemoptysis. Chest auscultation was normal. ECG showed sinus tachycardia with an S₁Q₃T₃ pattern and urgent bedside echocardiogram showed evidence of right heart strain.

Christian Becker

Respiratory insufficiency in the peripartum period has many potential causes, including PE, amniotic fluid embolism, pulmonary oedema due to tocolytic therapy and peripartum cardiomyopathy. Venous thromboembolism (VTE) is approximately 80 times more common in the first week post partum when compared with the general population¹ and PE is a leading cause of maternal mortality in the developed world (whereas postpartum haemorrhage is the most common cause of death in the developing world²). Haemoptysis in the setting of PE occurs in about 5% of patients, and represents pulmonary infarction.³ Given the acute onset of symptoms and echocardiographic findings, PE is the initial concern for this patient.

Klaus Meinhof and Robert Hiensch

Unfractionated heparin infusion was started. Shortly thereafter, the patient endorsed worsening dyspnoea and coughed up approximately 100 mL of bright red blood. Her heparin infusion was discontinued, and she was emergently intubated for hypoxaemia. Adequate oxygenation on the mechanical ventilator was difficult to maintain despite frequent endotracheal suctioning, use of high positive end-expiratory pressure and fraction of inspired oxygen (F_iO₂), initiation of neuromuscular blockade and frequent manual recruitment manoeuvres. Chest X-ray (CXR) showed diffuse, predominantly central opacities (figure 1), and a

complete blood count demonstrated a decrease in serum haemoglobin from 12.8 g/dL (prepartum) to 7.1 g/dL.

Christian Becker

The development of bilateral alveolar infiltrates in the setting of haemoptysis and an acute decrease in serum haemoglobin raises the concern for diffuse alveolar haemorrhage (DAH). Bronchoscopy with sequential bronchoalveolar lavage should be performed in the area of radiographic opacities. Alveolar haemorrhage is confirmed when serial lavage aliquots become progressively more haemorrhagic. DAH has many potential causes, including infections, inflammatory conditions and medications. Our patient's history of unexplored haematuria and proteinuria suggests a previously undiagnosed systemic disease, such as the pulmonary–renal syndromes, which present with DAH and focal segmental necrotising glomerulonephritis. In general, treatment of DAH focuses on respiratory stabilisation and reversal of the underlying cause. Immunosuppressive agents are used in immune-mediated disease settings, and can be used empirically in severe illness if there is high clinical suspicion while awaiting the appropriate confirmatory laboratory studies. In this case, the administration of heparin for presumed PE likely exacerbated her DAH. Other causes of DAH in the peripartum period that should be considered include acquired or congenital heart disease including mitral stenosis, malignancies such as metastatic gestational trophoblastic disease, amniotic fluid embolism and various infections.^{4–7}

Klaus Meinhof and Robert Hiensch

Emergent bedside flexible bronchoscopy showed diffusely haemorrhagic airways, but did not identify a focal bleeding source. When the bronchoscope was reinserted after suctioning, fresh blood was again seen in all airways, consistent with DAH. A bronchoalveolar lavage was not performed due to the patient's marginal oxygenation. The patient was transferred to the intensive care unit (ICU), where inhaled nitric oxide and inverse ratio pressure-controlled ventilation were initiated as rescue therapies. Owing to concern for immune-mediated DAH, pulse dose methylprednisolone (1000 mg/day) and plasmapheresis were urgently started.

CrossMark

To cite: Bunker DR, Meinhof KT, Hiensch RJ, et al. *Thorax* 2015;**70**:1095–1097.

Figure 1 Chest X-ray (CXR) on day of decompensation demonstrating diffuse, bilateral opacities.

Daniel Bunker

On further examination, the patient had no palpable purpura or other skin rashes associated with vasculitis and no synovitis. Laboratory results were negative for antinuclear antibodies, rheumatoid factor and antiglomerular basement membrane antibodies. Antineutrophil cytoplasmic antibody (ANCA) immunofluorescence, however, was positive at a dilution of 1:320, and ELISA for antimyeloperoxidase antibody was positive at 186 antibody units/mL. Given her previously noted proteinuria and haematuria, a renal biopsy was performed, showing a pauci-immune crescentic glomerulonephritis (figure 2). The patient was diagnosed with microscopic polyangiitis (MPA).

Olivia Ghaw

MPA is an ANCA-associated, nongranulomatous, necrotising vasculitis of the small vessels, with a tropism for the lung and kidney. It typically affects individuals in their fifth and sixth decade of life. Only three cases of MPA have been reported during pregnancy,^{8–10} and none immediately after parturition. In general, data regarding the effect of pregnancy on the activity of the primary systemic vasculitides are sparse because these syndromes are rare and primarily affect women past their

Figure 2 Renal biopsy light microscopy showing crescent formation.

reproductive age. Research on Takayasu's arteritis, a large-vessel vasculitis that usually affects young women, suggests that pregnancy does not affect disease activity.¹¹

Christian Becker

While the kidney is the most common organ involved in MPA, the lung is another frequent target organ. Pulmonary capillaritis leading to DAH is more commonly seen in MPA than in granulomatosis with polyangiitis (formally Wegener's granulomatosis),^{12–13} another ANCA-associated vasculitis. Case series suggest that anywhere from 12%¹⁴ to 48%¹⁵ of patients with MPA develop DAH during their disease course; this can also predate other extrathoracic manifestations by up to a year.¹⁴ Haemoptysis, as seen in our patient, is common in patients with MPA who develop DAH.^{15–16} For ANCA-associated vasculitis, retrospective data suggest that plasmapheresis improves outcomes in the setting of alveolar haemorrhage.¹² The exact role of plasmapheresis in disease induction therapy is the subject of an ongoing trial (<http://www.clinicaltrials.gov>; PEXIVAS; NCT00987389).

Daniel Bunker

The patient was continued on high-dose prednisone (1 mg/kg) and completed a total of six plasma exchanges. Her gas exchange improved significantly within 48 h of corticosteroid therapy and plasmapheresis, and she was successfully extubated after 6 days of mechanical ventilation. Pharmacological prophylaxis for VTE was not used during her hospitalisation because of her alveolar haemorrhage, though appropriate mechanical VTE prophylaxis was provided.

Olivia Ghaw

For decades, the standard of care for the treatment of ANCA-associated vasculitis was induction with cyclophosphamide. Recent data have shown that rituximab is at least equally effective¹⁷ and can also be used as maintenance therapy after induction.¹⁸ Seropositivity for antimyeloperoxidase antibodies is associated with lower risk of relapse than antiproteinase-3 antibodies;¹⁹ however, lung involvement predicts a higher risk of relapse.^{20–21}

Figure 3 Chest X-ray (CXR) 3 weeks after therapy showing resolution of infiltrates.

Daniel Bunker

Once extubated, induction therapy with rituximab was administered ($375 \text{ mg/m}^2 \times 4$ weekly doses).

Rituximab was chosen because of its favourable side-effect profile, specifically to avoid the risk of cyclophosphamide-induced premature ovarian failure. The excretion of rituximab in breast milk is unknown and thus the patient elected to avoid breast feeding. The patient was discharged in stable condition. Three weeks later, however, the patient developed acute shortness of breath and orthopnoea. CXR showed marked improvement in her pulmonary infiltrates (figure 3) and transthoracic echocardiogram showed normal biventricular function without a pericardial effusion. CT angiography of the chest revealed filling defects in the lower lobe pulmonary arterial tree, consistent with acute PE. Therapeutic systemic anticoagulation with unfractionated heparin was begun.

Christian Becker

ANCA-associated vasculitis is associated with a markedly increased risk of VTE, especially when the disease is active;²² the patient's recent ICU stay with neuromuscular blockade and her postpartum state are also risk factors. Given that her current CXR shows resolution of her previous DAH, the benefits of anticoagulation outweigh the risks in this setting.

Klaus Meinhof

The patient's shortness of breath improved with anticoagulation and she was discharged on warfarin. On follow-up evaluation 3 months later, the patient was doing well with no cardiopulmonary symptoms. Given the high rate of relapse of ANCA-associated vasculitis, maintenance therapy with rituximab is planned. The optimal duration of anticoagulation for VTE that occurs during pregnancy or immediately thereafter is unknown. Generally, the total duration of therapy should be 3–6 months from time of diagnosis for patients with transient risk factors, extending to at least 6 weeks post partum, given the significantly increased risk in the immediate postpartum period.^{23–24} For patients who have a persistent risk factor, longer duration of therapy is warranted.²⁵ We elected to treat our patient for 6 months with anticoagulation, with close monitoring for further venous thromboembolic events.

Christian Becker

A number of lessons can be drawn from this case:

1. Persistent haematuria and proteinuria during pregnancy should not be dismissed as this may be a sign of a potentially serious underlying disease.
2. One should never be wedded to a diagnosis; although it was reasonable to treat empirically for PE in a postpartum patient with acute-onset respiratory failure and haemoptysis, alternate diagnoses, even rare ones such as vasculitis with DAH, should be considered as additional clinical information becomes available or if the patient does not respond to appropriate therapy.
3. The different provider teams should approach each patient encounter with a degree of objectivity; failure to do so when the patient returned to the emergency department after her initial hospitalisation for DAH could have missed the subsequent diagnosis of PE.

Contributors All contributing authors were involved in the care of the patient. DRB drafted the initial manuscript. KTM summarised the clinical information. All authors participated in literature research and extension of the initial draft. All authors agreed on the final submitted version. DRB and KTM contributed equally to the work and are responsible for the overall content of the manuscript as guarantor.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Heit JA, Kobbervig CE, James AH, *et al.* Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. *Ann Intern Med* 2005;143:697–706.
- 2 Khan KS, Wojdyla D, Say L, *et al.* WHO analysis of causes of maternal death: a systematic review. *Lancet* 2006;367:1066–74.
- 3 Stein PD, Beemath A, Matta F, *et al.* Clinical characteristics of patients with acute pulmonary embolism: data from PLOPED II. *Am J Med* 2007;120:871–9.
- 4 Venkatram S, Muppuri S, Niazi M, *et al.* A 24-year-old pregnant patient with diffuse alveolar hemorrhage. *Chest* 2010;138:220–3.
- 5 Blyth DF, Soni MA, Moran NF. Massive hemoptysis in an immunocompromised pregnant woman with human immunodeficiency virus disease and active pulmonary tuberculosis. *Ann Thorac Surg* 2007;84:2085–6.
- 6 de Gussem EM, Lausman AY, Beder AJ, *et al.* Outcomes of pregnancy in women with hereditary hemorrhagic telangiectasia. *Obstet Gynecol* 2014;123:514–20.
- 7 Dhillon SS, Yendamuri S, Harris K, *et al.* Lymphangioma presenting as hemoptysis in pregnancy. *Am J Respir Crit Care Med* 2014;190:701–3.
- 8 Cetinkaya R, Odabas A, Gursan N, *et al.* Microscopic polyangiitis in a pregnant woman. *South Med J* 2002;95:1441–3.
- 9 Milne KL, Stanley KP, Temple RC, *et al.* Microscopic polyangiitis: first report of a case with onset during pregnancy. *Nephrol Dial Transplant* 2004;19:234–7.
- 10 Porres-Aguilar M, Figueroa-Casas JB, Porres-Muñoz M, *et al.* A 38-year-old pregnant woman with hemoptysis and acute renal failure. Microscopic polyangiitis. *Respiration* 2011;82:60–4.
- 11 Gatto M, Iaccarino L, Canova M, *et al.* Pregnancy and vasculitis: a systematic review of the literature. *Autoimmun Rev* 2012;11:A447–59.
- 12 Klemmer PJ, Chalemskulrat W, Reif MS, *et al.* Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. *Am J Kidney Dis* 2003;42:1149–53.
- 13 Ramsey J, Amari M, Kantrow SP. Pulmonary vasculitis: clinical presentation, differential diagnosis, and management. *Curr Rheumatol Rep* 2010;12:420–8.
- 14 Guillevin L, Durand-Gasselin B, Cevallos R, *et al.* Microscopic polyangiitis. *Arthritis Rheum* 1999;42:421–30.
- 15 Wilke L, Prince-Fiocco M, Fiocco GP. Microscopic polyangiitis: a large single-center series. *J Clin Rheumatol* 2014;20:179–82.
- 16 Lauque D, Cadranet J, Lazor R, *et al.* Microscopic polyangiitis with alveolar hemorrhage: a study of 29 cases and review of the literature. *Medicine* 2000;79:222–33.
- 17 Specks U, Merkel PA, Seo P, *et al.* Efficacy of remission-induction regimens for ANCA-associated vasculitis. *N Engl J Med* 2013;369:417–27.
- 18 Guillevin L, Pagnoux C, Karras A, *et al.* Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. *N Engl J Med* 2014;371:1771–80.
- 19 Walsh M, Flossmann O, Berden A, *et al.* Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. *Arthritis Rheum* 2012;64:542–8.
- 20 Hogan SL, Falk RJ, Chin H, *et al.* Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. *Ann Intern Med* 2005;143:621–31.
- 21 Pagnoux C, Hogan SL, Chin H, *et al.* Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. *Arthritis Rheum* 2008;58:2908–18.
- 22 Stassen PM, Derks RPH, Kallenberg CGM, *et al.* Venous thromboembolism in ANCA-associated vasculitis—incidence and risk factors. *Rheumatology (Oxford)* 2008;47:530–4.
- 23 Kamel H, Navi BB, Sriram N, *et al.* Risk of a thrombotic event after the 6-week postpartum period. *N Engl J Med* 2014;370:1307–15.
- 24 Bates SM, Greer IA, Middeldorp S, *et al.* VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141(2 Suppl):e691S–736S.
- 25 Kearon C, Akl EA, Comerota AJ, *et al.* Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2012;141(2 Suppl):e419S–94S.